A randomized, double-blind, placebo-controlled, single ascending dose study to demonstrate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 administered as intravenous infusion and subcutaneous injection in Japanese healthy volunteers.

Trial Profile

A randomized, double-blind, placebo-controlled, single ascending dose study to demonstrate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 administered as intravenous infusion and subcutaneous injection in Japanese healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2012

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Nov 2007 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 21 Jun 2007 Status change from recruiting to in progress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top